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Abstract. The development of cisplatin resistance in human 
cancers is controlled by multiple genes and leads to therapeutic 
failure. Hypermethylation of specific gene promoters is a key 
event in clinical resistance to cisplatin. Although the usage of 
multiple promoters is frequent in the transcription of human 
genes, the role of alternative promoters and their regulatory 
sequences have not yet been investigated in cisplatin resistance 
genes. In a new approach, we hypothesized that human cancers 
exploit the specific transcription factor-binding sites (TFBS) 
and CpG islands (CGIs) located in the alternative promoters of 
certain genes to acquire platinum drug resistance. To provide a 
useful resource of regulatory elements associated with cisplatin 
resistance, we investigated the TFBS and CGIs in 48 alterna-
tive promoters of 14 hypermethylated cisplatin resistance genes 
previously reported. CGIs prone to methylation were identi-
fied in 28 alternative promoters of 11 hypermethylated genes. 
The majority of alternative promoters harboring CGIs (93%) 
were clustered in one phylogenetic subclass, whereas the ones 
lacking CGIs were distributed in two unrelated subclasses. 
Regulatory sequences, initiator and TATA-532 prevailed over 
TATA-8 and were found in all the promoters. B recognition 
element (BRE) sequences were present only in alternative 
promoters harboring CGIs, but CCAAT and TAACC were 
found in both types of alternative promoters, whereas down-
stream promoter element sequences were significantly less 
frequent. Therefore, it was hypothesized that BRE and CGI 
sequences co-localized in alternative promoters of cisplatin 
resistance genes may be used to design molecular markers for 
drug resistance. A more extensive knowledge of alternative 
promoters and their regulatory elements in clinical resistance 
to cisplatin is likely to usher novel avenues for sensitizing 
human cancers to treatment.
Introduction
The success of platinum drugs in the treatment of various 
types of cancer has been challenged by the hamper of intrinsic 
and acquired resistance. Cell and molecular biology research 
over several decades has provided insight into this problem 
and has demonstrated that alterations in drug influx and 
efflux, detoxification via glutathione and glutathione transfer-
ases and enhanced DNA repair (1-3) are all involved, either 
singly or in combination, in cisplatin resistance. However, 
it remains puzzling that genomic expression patterns of 
platinum-sensitive̸-resistant determinants in several cell 
lines, including squamous cell carcinoma of the head and 
neck, bladder and ovarian cancers, do not always correlate 
with the results of biochemical analyses (4-6). Additionally, 
epigenetic changes in the DNA methylation profiles during 
cancer development are associated with the acquisition of 
cisplatin resistance (6-9). However, the problem of platinum 
resistance at the genomic and epigenomic levels has not been 
clearly defined. Therefore, it is paramount to gain a better 
understanding of gene expression machinery components that 
control platinum resistance genes. A promising approach to 
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these questions appears to be the characterization of regulatory 
elements, CpG islands (CGIs) and transcription factor-binding 
sites (TFBS) in alternative promoters of genes that have been 
validated and their association with cisplatin resistance proven.
It has been well established that alternative promoters are 
involved in the transcription of nearly half of all eukaryotic 
genes and are considered one of the main molecular charac-
teristics of eukaryotic genomes (10,11). Overall, alternative 
promoters have been suggested to add significant flexibility and 
greater diversity to the regulation of gene expression (10-16). 
The functional significance of alternative promoters and their 
role in disease development and progression remains unclear, 
except for a few well characterized genes, such as the tumor 
suppressor p53, lymphoid enhancer-binding factor 1, insulin 
growth factor 2 and guanine nucleotide-binding protein 
α-stimulating genes, where these sequences are aberrantly 
activated, developmentally regulated or silenced (11). In addi-
tion, alternative promoters have been shown to regulate the 
expression of paired box homeotic gene 6 in various tissue 
types and play crucial roles in the development of the eye, 
brain, olfactory system and endocrine pancreas (17).
The TFBS and the CGIs targeted for DNA methylation, 
significantly affect the functional activities of alternative 
promoters (6-9,18,19). To date, the role and molecular char-
acteristics of alternative promoters have not been investigated 
in platinum drug resistance. The present study mapped the 
distribution of TFBS and CGIs in 48 alternative promoters 
involved in the regulation of 14 hypermethylated genes, known 
to be associated with the development of cisplatin resistance.
Materials and methods
Alternative promoters of cisplatin resistance genes. A total 
of 14 genes known to contribute to cisplatin resistance and to 
be specifically hypermethylated in resistant cell lines, but not 
in the sensitive parental cell lines (9), were selected for this 
study. The genes were screened for the presence of alternative 
promoters and regulatory elements (CGIs and TFBS) within 
these sequences. The chromosomal map locations of cisplatin 
genes were searched in the GenBank database (http://www.
ncbi.nlm.nih.gov/genbank/) and the alternative promoters for 
each gene were searched in the Transcriptional Regulatory 
Element Database (TRED; https://cb.utdallas.edu/cgi-bin/
TRED/tred.cgi?process=home). The length of the promoter 
sequence was set to 1,000 base pairs (bps), which were 
numbered along the sequence of the promoter relative to the 
transcription start site (TSS). The sequence of bps upstream 
the TSS was numbered with a negative sign, whereas down-
stream bases were identified with a positive sign.
Search for regulatory elements in the alternative promoters. 
The alternative promoters of 14 cisplatin resistance genes 
were analyzed for TFBS, namely, TATA-8 (TATAWAWR) 
and TATA-532 (HWHWWWWR, excluding HTYTTTWR, 
CAYTTTWR, MAMAAAAR and CTYAAAAR) elements, 
initiator (INR; YYANWYY), CCAAT and its inverted 
sequence TAACC, B recognition element (BRE; SSRCGCC) 
and downstream promoter element (DPE; RGWCGTG) 
sequences (20,21). CGIs in alternative promoters were searched 
in a 100-bp window (N=100) moving across the sequence at 
1-bp intervals. The parameter sets used to search for CGIs in 
the alternative promoters were as follows: observed/expected 
(O/E) CpG ≥0.6 and %GC >55% (22‑25). The O/E ratio for 
CpG was calculated according to the equation reported by 
Gardiner-Garden and Frommer (22).
Construction of phylogenetic tree. To investigate the evolu-
tionary associations among the 48 alternative promoter 
sequences and to group the related sequences into specific 
categories, a phylogenetic tree was constructed using the 
Phylogenetic Tree application in the MATLAB Bioinformatics 
toolbox to probe the interrelationships and linking the tree 
nodes. The alternative promoter sequences and their deriva-
tives were drawn using a hierarchical diagram.
Statistical analysis. The promoter sequences were analyzed 
using Perl, C++ and Excel software. The independence of each 
promoter element was examined using the Fisher's exact prob-
ability test.
Results
Hypermethylated genes in acquired cisplatin resistance. 
Chang et al (9) published an elegant study of specific genes 
that selectively undergo methylation in cisplatin-resistant cell 
lines, but not in their cisplatin-sensitive isogenic parent cell 
counterparts. The authors found that a set of 14 genes were 
silenced in the cisplatin-resistant cells and confirmed that 
promoter methylation, as determined by sodium bisulfite 
sequencing, accounted for the lack of gene expression. A 
number of these genes were also reactivated by azacytidine 
treatment of resistant cells (9). We used this panel of meth-
ylated genes for analysis of alternative promoters and their 
regulatory characteristics in cisplatin resistance. A list of these 
genes and their designations is provided in Table I. We also 
mapped the locations of these genes to their chromosomes and 
these sites are represented in Table I.
Genomic context of alternative promoters of cisplatin 
hypermethylated genes. A search through TRED identified 
48 promoters for the 14 hypermethylated cisplatin resistance 
genes reported by Chang et al (9). These promoters were 
analyzed to identify the CGIs and TFBS (Fig. 1 and Table II). 
The number of identified alternative promoters for each gene 
varied between 2 and 6 (Fig. 1A) and were located on 9 chro-
mosomes (Fig. 1B). Chromosome 1 and the long arm ‘q’ were 
found to host a higher number of genes and alternative promoters 
compared to other chromosomes and short arms (Fig. 1B). Of 
the 14 cisplatin resistance genes, 5 (35.71%) were located on 
chromosome 1, while of all the promoters investigated, 18 
(37.5%) were located on this chromosome. However, the distri-
butions of alternative promoters and genes were almost equal 
on forward and reverse strands of the chromosomes: 6 genes 
(43%) were located on the reverse strands and 8 genes (57%) on 
the forward strands (Fig. 1C); 26 promoters (54%) were on the 
reverse strands and 22 (46%) on the forward strands (Fig. 1D).
CGIs and TFBS. CGIs were identified in 28 alternative 
promoters of 11 cisplatin resistance genes, while 3 genes, 
namely the C4-binding protein β (C4BPB), chromosome 8 
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open reading frame 4 (C8orf4) and cytidine deaminase (CDA) 
genes, exhibited no CGIs (Table II). As shown in Table II, 
the INR and TATA-532 sequences prevailed over TATA-8 
sequences. We also observed that the alternative promoters of 
cisplatin resistance genes were rich in TATA-8 and TATA-532 
sequences, although these varied significantly in their frequen-
cies. For example, the four promoters of opsin 3 (OPN3), namely 
44257, 2157, 114168 and 118881, which lack CGIs, contained 
13-35 TATA-532 elements. Our analysis also demonstrated 
that each of two promoters, melanoma cell adhesion molecule 
(MCAM)‑117653 (lacked CGI) and S100P‑31251 (harbored 
two CGIs), contained 10 TATA-8 sequences. Furthermore, the 
alternative promoters that harbored CGIs contained TATA-532 
sequences in a wide range, from 1 to 22. The CCAAT and its 
inverted sequence TAACC, BRE and DPE sequences were 
not as frequent as INR and TATA-532 sequences. Another 
interesting observation was associated with BRE sequences: 
we noticed that the identified 48 BRE sequences were present 
Table I. Description of functional activity and map locations for 14 genes associated with cisplatin resistance.
Genes GenBank ID Description Map location
ALCAM NM_001627 Activated leukocyte cell adhesion molecule 3q13.1, forward strand
B4GALT1 NM_001497 UDP-Gal:βGlcNAc β1,4-galactosyltransferase, polypeptide 1 9p13, reverse strand
C4BPB NM_000716 C4-binding protein β 1q32, forward strand
C8orf4 NM_020130 Chromosome 8 open reading frame 4 8p11.2, forward strand
CDA NM_001785 Cytidine deaminase 1p36.2-p35, forward strand
CRIP1 NM_001311 Cysteine-rich protein 1 (intestinal) 14q32.33, forward strand
G0S2 NM_015714 G0/G1 switch 2 1q32.2-41, forward strand
LAMB3 NM_000228 Laminin β3 1q32, reverse strand
MCAM NM_006500 Melanoma cell adhesion molecule 11q23.3, reverse strand
OPN3 NM_014322 Opsin 3 1q43, reverse strand
S100P NM_005980 S100 calcium-binding protein P 4p16, forward strand
SAT1 NM_002970 Spermidine/spermine N1 acetyltransferase 1 Xp22.1, forward strand
TM4SF1 NM_014220 Transmembrane 4 L six family member 1 3q21-q25, reverse strand
TUBB2A NM_001069 Tubulin β2A class IIa 6p25, reverse strand
Figure 1. Analysis of 48 alternative promoters for the selected 14 genes associated with cisplatin resistance. (A) Number of alternative promoters for each gene. 
(B) Map locations of the 14 cisplatin genes and their alternative promoters on the chromosomes and the chromosome arms (p or q). (C) Number of cisplatin 
resistance genes on the p and q arms of the reverse and forward strands. (D) Number of alternative promoters of cisplatin genes on the reverse and forward 
strands of the p and q arms of chromosomes. ALCAM, activated leukocyte cell adhesion molecule; B4galt1, UDP‑Gal:βGlcNAc β1,4-galactosyltransferase, 
polypeptide 1; C4BPB, C4-binding protein β; C8orf4, chromosome 8 open reading frame 4; CDA, cytidine deaminase; CRIP1, cysteine-rich protein 1; 
G0S2, G0/G1 switch 2; LAMB3, laminin β3; MCAM, melanoma cell adhesion molecule; OPN3, opsin 3; S100P, S100 calcium-binding protein P; SAT1, 
spermidine̸spermine N1 acetyltransferase 1; TM4SF1, transmembrane 4 L six family member 1; TUBB2A, tubulin β2A class IIa.
  A   B
  C   D
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in 20 promoters of 9 cisplatin genes that harbored CGIs and 
were absent in other alternative promoters that lacked CGIs.
Phylogenetic tree analysis of alternative promoter sequences. 
A phylogenetic tree was created from a set of 48 alterna-
tive promoter sequences of the 14 cisplatin resistance genes 
(Fig. 2). Two main clustering patterns were observed, namely 
A and B, which may be further divided into subclasses and 
secondary classes within each category. The first main class 
(A) included 38 alternative promoters and the second main 
class (B) included 10 promoters. Furthermore, the first main 
class (A) may be divided into two subclasses, namely C and D; 
subclass C contained 30 alternative promoters, of which 
26 contained CGIs. Groups E and F were identified in 
subclass C, which were represented by 19 and 11 alternative 
promoters, respectively. Group E included 18 alternative 
promoters with CGIs and 1 promoter (S100P-117263) without 
CGIs; group F included 8 alternative promoters with 
CGIs: SAT-43140, -43141 and -115065, TUBB2A-37272, 
G0S2-119612 and -1833 and LAMB3-2377 and -2378. The 
small subclass (D) contained 8 promoters, with 7 promoter 
sequences lacking CGIs: TM4SF1-30388, -30390 and -30389, 
OPN3-2157 and -44257 and C8norf4-39909 and -121250. 
Of the 10 alternative promoters in class B, 9 did not have 
CGIs: C4BPB-113384, -1813 and -1814, LAMB3-113646, 
B4GALT1-118955, MCAM-117653, OPN3-114168 and 
-118881 and TM4SF1-118807. The remaining promoter in 
this class, TUBB2A-113646, was characterized by the pres-
ence of 22 sequences of TATA-532 type and harbored CGIs. 
The evolutionary distances between the two major classes A 
and B and subclasses C and D were in the range of 0.0125 
and 0.03125, respectively, exhibiting weak evolutionary ties 
between them; however, stronger ties were observed among 
the alternative promoters in group E and F within subclass C, 
which were composed mainly from alternative promoters with 
CGIs (93%). The alternative promoters that lacked CGIs were 
distributed in two unrelated groups, B and D.
Discussion
We selected a panel of genes specifically known to undergo 
methylation in cisplatin-resistant cell lines (9) and characterized 
the alternative promoters and regulatory sequences associ-
ated therewith. The exact mechanisms by which these genes 
contribute to cisplatin resistance has not been fully elucidated; 
however, a number of these were shown to be inducible by cispl-
atin treatment in sensitive cells and silenced in sensitive isogenic 
cells (9). Recent findings support a prominent role for alterna-
tive promoters in cell type and human tissue type‑specific gene 
expression (26). Considering that the transcription machinery 
utilizes alternative promoters for regulating differential tran-
scription (10,16) and the aberrant use of one alternative promoter 
over another may result in disease, including cancer (11), we 
hypothesized that cisplatin resistance may be mediated by a 
differential usage of alternative promoters with variable regula-
tory sequences, TFBS and CGIs. Transcription factors and their 
binding sites in a given promoter are key elements in controlling 
the rate and extent of mRNA synthesis (19,27). However, the 
interaction between transcription factors and cis-regulatory 
modules, which contain the TFBS in promoter sequences, has 
not been clearly determined (27-33). Seven types of TFBS, 
namely INR, TATA-8, TATA-532, BRE, DPE, CCAAT and 
TAACC are well recognized (20,21). Our results demon-
strated that 11 alternative promoters have TATA-8 sequences 
and 47 promoters contain TATA-532 sequences. It has been 
reported that ~76% of human core promoters lack TATA‑like 
elements (20) and only 10-20% of promoters contain the TATA 
sequences (34). Of note, our study was not restricted to core 
Figure 2. Phylogenetic tree generated for the 48 DNA sequences of the alternative promoters of 14 cisplatin resistance genes.
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Table II. TFBS and CGIs in the 48 alternative promoters of 14 genes associated with cisplatin resistance.
Genesa Promoter ID INR T8 T532 CCAAT TAACC BRE DPE CGIs
ALCAM 114029 5 0 5 1 0 1 1 +
 29583 7 0 7 1 0 1 0 +
 29584 11 0 8 0 0 0 0 +
B4GALT1 42895 6 0 1 0 2 4 0 +
 113955 5 0 18 0 0 0 0 -
C4BPB 1813 12 0 15 0 1 0 0 -
 1814 11 0 11 0 1 0 0 -
 113384 12 0 15 0 1 0 0 -
C8orf4 39909 10 0 10 0 0 0 0 -
 121250 10 0 10 0 0 0 0 -
CDA 279 12 0 5 0 0 0 0 -
 114145 12 0 5 0 0 0 0 -
CRIP1 12302 4 0 1 0 1 2 0 +
 12303 0 0 1 0 0 1 0 +
 113817 4 0 1 0 1 2 0 +
G0S2 1832 2 0 7 0 0 1 0 +
 1833 3 0 13 0 1 1 0 +
 119612 3 0 13 0 1 1 0 +
LAMB3 2377 7 1 6 0 1 0 0 +
 2378 9 1 8 0 1 0 0 +
 2379 13 1 13 3 3 0 0 -
 113034 6 0 7 1 1 0 0 -
MCAM 7410 4 0 0 0 0 3 0 +
 7411 4 0 2 0 2 0 0 +
 117653 5 10 45 0 0 0 0 -
OPN3 2156 7 0 3 1 0 5 0 +
 44257 12 0 13 0 0 0 0 -
 2155 7 0 3 1 0 5 0 +
 2157 14 0 28 1 1 0 0 -
 114168 8 2 27 2 1 0 0 -
 118881 13 1 35 1 0 0 0 -
S100P 31250 6 0 4 0 0 0 0 +
 31251 4 10 50 0 0 0 0 +
 117263 3 0 4 0 0 0 0 -
SAT1 43141 6 0 9 1 1 3 0 +
 43140 6 0 9 1 1 3 0 +
 115065 6 0 9 1 1 3 0 +
TM4SF1 30388 8 0 15 2 0 0 0 -
 30389 8 0 14 2 0 0 0 -
 30390 7 0 14 2 0 0 0 -
 30391 10 0 2 0 2 0 0 +
 30392 11 0 6 0 0 1 0 +
 118807 7 1 33 2 0 0 0 -
TUBB2A 37269 6 1 1 0 0 3 0 +
 37270 6 1 1 0 0 3 0 +
 37271 6 1 1 0 0 3 0 +
 37272 10 0 14 1 0 0 0 +
 113646 8 0 22 0 0 2 0 +
aFor gene description, see Table I. TFBS: T8, TATAWAWR; T532, HWHWWWWR (excluding HTYTTTWR, MAMAAAAAR and 
CTYAAAAR); BRE, SSRCGCC; DPE, RGWCGTG; INR, YYANWYY; CCAAT and its inverted sequence TAACC (20,21). Parameter sets 
used to search for CGIs in the alternative promoters: observed/expected CpG ≥0.6 and %GC >55% (22‑25). + and ‑ indicate presence and 
absence of CGIs. TFBS, transcription factor-binding sites; CGIs, CpG islands; INR, initiator; T8, TATA-8; T532, TATA-532; BRE, B recogni-
tion element; DPE, downstream promoter element.
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promoters, which are located ~40 bp up- and downstream of the 
TSS (35), but included the entire length of 1,000 bp that included 
700 bp upstream and 300 bp downstream of TSS, as given by 
TRED. Furthermore, our results demonstrated that CCAAT, 
TAACC, BRE and DPE sequences were not as frequent as 
TATA sequences. Seventeen alternative promoters (35.4%) 
contained CCAAT; 19 (39.6%) contained TAACC, 20 (41.6%) 
contained BRE and one (2%) contained DPE. The percentage 
obtained for CCAAT was similar to that reported previously, 
reflecting its ubiquity in mammalian promoters (21,36). As the 
mechanism associated with cisplatin resistance is multifacto-
rial (1-3), our results suggest that the genes encoding cisplatin 
resistance harbor more than one option to initiate their tran-
scripts to enhance the efficiency of mRNA production.
It has been well documented that CGIs are prone to DNA 
methylation and this epigenetic mechanism is associated with 
gene silencing, initiation and maintenance of malignancy 
and drug resistance (6-9,37-39). Hypermethylation in CGIs 
and subsequent gene inactivation contributes to cisplatin 
resistance (9), as described earlier in this study. In the present 
study, we demonstrated that 11 out of the 14 genes reported by 
Chang et al (9) have 28 promoters harboring CGIs. However, 
the remaining 3 genes, namely C4BPB, C8orf4 and CDA, 
lacked discernible CGIs, raising the possibility of other mech-
anisms. The majority of alternative promoters harboring CGIs 
(93%) were clustered in one phylogenetic subclass, indicating 
relatively strong evolutionary ties among them. Thus, it may 
be hypothesized that the use of promoters with less frequent 
DNA methylation hotspots may assist the genes in escaping 
the epigenetic modifications and enable continued and effi-
cient expression. Furthermore, we demonstrated that BRE and 
CGI sequences co-localized in the alternative promoters of 
cisplatin resistance genes (Table II) and this property may be 
utilized to design molecular markers for resistance to cisplatin 
and/or drugs. Such an approach will involve designing specific 
primers for amplifying DNA sequences that include BRE and 
a downstream segment of alternative promoter and a short exon 
region of the gene in question. A more detailed understanding 
of the functionality of the alternative promoters in cisplatin 
resistance is likely to have other applications; for example, it 
may be possible to design novel anticancer drugs that interact 
with specific promoter sequences, e.g., G‑rich sequences which 
may form DNA G-quadruplexes (40-42). In addition, future 
research may make use of novel synthetic biology methods to 
build molecular models of various components of alternative 
promoters (43-46) to overcome drug resistance and enable 
more effective and personalized cancer therapies.
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